Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 14/20 | 0.54 |
| ▸ | MAPK13 | O15264 | 13/20 | 0.54 |
| ▸ | MAPK12 | P53778 | 13/20 | 0.54 |
| ▸ | MAPK11 | Q15759 | 13/20 | 0.54 |
| ▸ | GCGR | P47871 | 5/20 | 0.54 |
| ▸ | RAF1 | P04049 | 8/20 | 0.54 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.54 |
| ▸ | BRAF | P15056 | 5/20 | 0.53 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28404728 | 0.89 | MAPK14 (0.58) | ALOX5MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4434506 | 0.84 | MAPK14 (0.66) | ALOX5MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL3278317 | 0.83 | KDM4E (0.58) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL7236344 | 0.83 | ALOX5 (0.79) | ALOX5MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL16511391 | 0.83 | ALOX5 (0.79) | ALOX5MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL26110690 | 0.79 | MAPK13 (0.52) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL1929921 | 0.78 | KDM4E (0.55) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL28403339 | 0.78 | MAPK14 (0.64) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL28406311 | 0.78 | MAPK14 (0.45) | MAPK14MAPK13MAPK12MAPK11GCGR | |
| SCHEMBL28400735 | 0.77 | MAPK13 (0.51) | MAPK14MAPK13MAPK12MAPK11GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487436-A4 | COMBINATION THERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS | SIGNAL PHARM INC (US) | 2009-06-03 | — | — | EP | disclosed |
| EP-1487436-A1 | COMBINATION THERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS | Signal Pharmaceuticals, Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| WO-2003075917-A1 | COMBINATION THERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS | SIGNAL PHARMACEUTICALS, INC. (US) | 2003-09-18 | — | — | WO | disclosed |
| EP-0623126-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1994-11-09 | — | — | EP | disclosed |
| WO-1993014081-A1 | IMIDAZOLE DERIVATIVES AND THEIR USE AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-07-22 | — | — | WO | disclosed |